awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q53817434-30420034-FE1E-4B71-B096-DBB569188E47
Q53817434-30420034-FE1E-4B71-B096-DBB569188E47
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53817434-30420034-FE1E-4B71-B096-DBB569188E47
A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.
P2860
Q53817434-30420034-FE1E-4B71-B096-DBB569188E47
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53817434-30420034-FE1E-4B71-B096-DBB569188E47
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
a8c0aa6388bcaefed9e5f717a069bd0cc009bc2b
P2860
NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.